ResMed Inc. (RMD) Shares Sold by Voya Investment Management LLC

Share on StockTwits

Voya Investment Management LLC reduced its stake in ResMed Inc. (NYSE:RMD) by 1.9% during the second quarter, according to its most recent filing with the SEC. The fund owned 106,527 shares of the medical equipment provider’s stock after selling 2,069 shares during the quarter. Voya Investment Management LLC owned 0.07% of ResMed worth $11,034,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of RMD. Millennium Management LLC boosted its holdings in shares of ResMed by 2,526.7% in the 1st quarter. Millennium Management LLC now owns 769,536 shares of the medical equipment provider’s stock worth $75,776,000 after buying an additional 740,239 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of ResMed by 191.2% in the 1st quarter. JPMorgan Chase & Co. now owns 971,754 shares of the medical equipment provider’s stock worth $95,687,000 after buying an additional 638,038 shares during the last quarter. Los Angeles Capital Management & Equity Research Inc. boosted its holdings in shares of ResMed by 1,082.0% in the 2nd quarter. Los Angeles Capital Management & Equity Research Inc. now owns 445,260 shares of the medical equipment provider’s stock worth $46,120,000 after buying an additional 407,590 shares during the last quarter. Canada Pension Plan Investment Board boosted its holdings in shares of ResMed by 209.7% in the 2nd quarter. Canada Pension Plan Investment Board now owns 260,806 shares of the medical equipment provider’s stock worth $27,014,000 after buying an additional 176,589 shares during the last quarter. Finally, Standard Life Aberdeen plc boosted its holdings in shares of ResMed by 499.2% in the 2nd quarter. Standard Life Aberdeen plc now owns 151,243 shares of the medical equipment provider’s stock worth $15,667,000 after buying an additional 126,002 shares during the last quarter. 63.81% of the stock is currently owned by institutional investors.

In other news, insider David Pendarvis sold 2,810 shares of the company’s stock in a transaction dated Friday, August 3rd. The stock was sold at an average price of $106.20, for a total transaction of $298,422.00. Following the sale, the insider now directly owns 101,893 shares in the company, valued at $10,821,036.60. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, insider James Hollingshead sold 600 shares of the company’s stock in a transaction dated Wednesday, August 1st. The shares were sold at an average price of $105.93, for a total value of $63,558.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 13,420 shares of company stock worth $1,480,182. Insiders own 1.77% of the company’s stock.

A number of equities analysts recently weighed in on the stock. Zacks Investment Research raised shares of ResMed from a “sell” rating to a “hold” rating in a report on Tuesday, July 31st. Goldman Sachs Group initiated coverage on shares of ResMed in a report on Sunday, July 1st. They set a “buy” rating on the stock. Two research analysts have rated the stock with a sell rating, six have given a hold rating and four have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $81.60.

NYSE RMD traded up $1.41 during trading on Friday, hitting $103.25. 652,391 shares of the company’s stock traded hands, compared to its average volume of 684,547. The company has a market cap of $16.46 billion, a PE ratio of 29.25, a price-to-earnings-growth ratio of 2.94 and a beta of 0.87. ResMed Inc. has a 12-month low of $77.27 and a 12-month high of $116.64. The company has a quick ratio of 1.56, a current ratio of 2.08 and a debt-to-equity ratio of 0.13.

ResMed (NYSE:RMD) last released its quarterly earnings data on Thursday, August 2nd. The medical equipment provider reported $0.95 EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.95. The business had revenue of $623.63 million for the quarter, compared to the consensus estimate of $622.78 million. ResMed had a net margin of 13.49% and a return on equity of 24.74%. The company’s revenue was up 12.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.77 earnings per share. As a group, equities research analysts anticipate that ResMed Inc. will post 3.71 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, September 20th. Shareholders of record on Thursday, August 16th were issued a dividend of $0.37 per share. The ex-dividend date was Wednesday, August 15th. This is an increase from ResMed’s previous quarterly dividend of $0.35. This represents a $1.48 annualized dividend and a yield of 1.43%. ResMed’s dividend payout ratio is 41.93%.

ResMed Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep disordered breathing, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes.

Featured Story: How Do You Calculate Return on Equity (ROE)?

Institutional Ownership by Quarter for ResMed (NYSE:RMD)

Receive News & Ratings for ResMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.